Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Biopeptide CL (Palmitoyl Tripeptide-5)
Overview
Palmitoyl Tripeptide-5 is a synthetic lipopeptide consisting of a tripeptide sequence conjugated to palmitic acid to enhance dermal penetration. The peptide is designed to stimulate collagen synthesis by mimicking the activity of thrombospondin-1, a matricellular protein involved in extracellular matrix remodeling.
Mechanism of Action
Its therapeutic rationale centers on attenuating photoaging and improving skin elasticity through upregulation of Types I and III collagen in dermal fibroblasts.
Research Summary & Key Findings
In vitro studies have demonstrated increased collagen gene expression and decreased matrix metalloproteinase activity in cultured human fibroblasts. Small-scale human pilot studies reported improvements in skin roughness and fine lines after 12 weeks of topical application, though peer-reviewed controlled trial data remain limited.
Clinical Status
Biopeptide CL (Palmitoyl Tripeptide-5) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
References
Primary literature
- PubMed: "Biopeptide CL"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Biopeptide CL"
Registered interventional and observational studies, including status and phase.
- PubChem: "Biopeptide CL"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Dermatology
Afamelanotide (Scenesse)
FDA ApprovedA synthetic 13-amino acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH) with a substitution of norleucine a...
View detailsArgireline (Acetyl Hexapeptide-8)
InvestigationalArgireline is a synthetic six amino acid peptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) designed to attenuate neurotransmitter...
View detailsMatrixyl (Palmitoyl Pentapeptide-4)
InvestigationalMatrixyl is a lipopeptide composed of a pentapeptide sequence (Lys-Thr-Thr-Lys-Ser) attached to a palmitic acid moiety t...
View detailsMatrixyl 3000
InvestigationalMatrixyl 3000 is a proprietary combination of two lipopeptides: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapept...
View detailsNo lawful pathway today
Biopeptide CL (Palmitoyl Tripeptide-5) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.